المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: ISSN: 2589-5559.

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie‐noëlle, Hiriart, Jean‐baptiste, Houssel‐debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges‐philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Hôpital Claude Huriez Lille, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), CHU Clermont-Ferrand, CHU Trousseau Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg), Les Hôpitaux Universitaires de Strasbourg (HUS), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Hôpital Paul Brousse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département d'Hépato-Gastroentérologie et de Transplantation Hépatique CHU Saint-Eloi, Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Université de Montpellier (UM), Hôpital Beaujon AP-HP, Hôpitaux Universitaires de Genève (HUG), Hôpital Archet 2 Nice (CHU), Hôpital de la Timone CHU - APHM (TIMONE), Centre Hospitalier Universitaire CHU Grenoble (CHUGA), Hôpital Haut-Lévêque CHU Bordeaux, CHU Bordeaux, Service Radiologie et imagerie médicale - Rangueil / Larrey CHU Toulouse, Pôle imagerie médicale CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Ressources Autisme de Bourgogne (CHU de Dijon) (CRAB), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université Paris-Saclay

المصدر: ISSN: 1478-3223.

مصطلحات موضوعية: cardiovascular DRI, donor risk index DSE, dobutamine stress echocardiography GFR, glomerular filtration rate HCC, hepatocellular carcinoma HCV, hepatitis C virus HDL-c, High-Density Lipoproteins Cholesterol ICA, invasive coronary angiography IQR, interquartile range LDL-c, Low-Density Lipoproteins LT, liver transplantation MELD, model for end-stage liver disease MDRD, Modification of Diet in Renal Disease MS, metabolic syndrome mTOR-i, m-TOR inhibitor NAFLD, non-alcoholic fatty Liver disease NASH, nonalcoholic steatohepatitis OSAS, Obstructive Sleep Apnoea syndrome TACE, Trans-Arterial Chemo-Embolization TTE, Transthoracic Echocardiography liver transplantation, metabolic syndrome, NAFLD, survival, Coronary Artery Disease, CKD, Chronic Kidney Disease, CNI, calcineurin inhibitor, COPD, Chronic Obstructive Pulmonary Disease

الوصف: International audience ; Background and Aims: Liver transplantation (LT) is the treatment of end-stage nonalcoholic liver disease (NAFLD), that is decompensated cirrhosis and/or complicated by hepatocellular carcinoma (HCC). Few data on long-term outcome are available. The aim of this study was to evaluate overall patient and graft survivals and associated predictive factors. Method: This retrospective multicentre study included adult transplant patients for NAFLD cirrhosis between 2000 and 2019 in participating French-speaking centres. Results: A total of 361 patients (69.8% of male) were included in 20 centres. The median age at LT was 62.3 years [57.4-65.9] and the median MELD score was 13.9 [9.1-21.3]; 51.8% of patients had HCC on liver explant. Between 2004 and 2018, the number of LT for NAFLD cirrhosis increased by 720%. A quarter of the patients had cardiovascular history before LT. Median follow-up after LT was 39.1 months [15.8-72.3]. Patient survival at 1, 5 and 10 years after LT was 89.3%, 79.8% and 68.1% respectively. The main causes of death were sepsis (37.5%), malignancies (29.2%) and cardiovascular events (22.2%). In multivariate analysis, three risk factors for overall mortality after LT were recipient pre-LT BMI < 32 kg/m 2 at LT time (OR: 2.272; p = .012), pre-LT angioplasty during CV checkup (OR: 2.916; p = .016), a combined donor and recipient age over 135 years (OR: 2.020; 95%CI: p = .035). Conclusion: Survival after LT for NAFLD cirrhosis is good at 5 years. Donor and recipient age, and cardiovascular history, are major prognostic factors to consider.

العلاقة: hal-04165914; https://hal.science/hal-04165914Test; https://hal.science/hal-04165914/documentTest; https://hal.science/hal-04165914/file/LIV-42-2428.pdfTest

الإتاحة: https://doi.org/10.1111/liv.15385Test
https://hal.science/hal-04165914Test
https://hal.science/hal-04165914/documentTest
https://hal.science/hal-04165914/file/LIV-42-2428.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie‐noëlle, Hiriart, Jean‐baptiste, Houssel‐debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges‐philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Hôpital Claude Huriez Lille, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), CHU Clermont-Ferrand, CHU Trousseau Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg), Les Hôpitaux Universitaires de Strasbourg (HUS), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Hôpital Paul Brousse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département d'Hépato-Gastroentérologie et de Transplantation Hépatique CHU Saint-Eloi, Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Université de Montpellier (UM), Hôpital Beaujon AP-HP, Hôpitaux Universitaires de Genève (HUG), Hôpital Archet 2 Nice (CHU), Hôpital de la Timone CHU - APHM (TIMONE), Centre Hospitalier Universitaire CHU Grenoble (CHUGA), Hôpital Haut-Lévêque CHU Bordeaux, CHU Bordeaux, Service Radiologie et imagerie médicale - Rangueil / Larrey CHU Toulouse, Pôle imagerie médicale CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Ressources Autisme de Bourgogne (CHU de Dijon) (CRAB), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université Paris-Saclay

المصدر: ISSN: 1478-3223.

مصطلحات موضوعية: cardiovascular DRI, donor risk index DSE, dobutamine stress echocardiography GFR, glomerular filtration rate HCC, hepatocellular carcinoma HCV, hepatitis C virus HDL-c, High-Density Lipoproteins Cholesterol ICA, invasive coronary angiography IQR, interquartile range LDL-c, Low-Density Lipoproteins LT, liver transplantation MELD, model for end-stage liver disease MDRD, Modification of Diet in Renal Disease MS, metabolic syndrome mTOR-i, m-TOR inhibitor NAFLD, non-alcoholic fatty Liver disease NASH, nonalcoholic steatohepatitis OSAS, Obstructive Sleep Apnoea syndrome TACE, Trans-Arterial Chemo-Embolization TTE, Transthoracic Echocardiography liver transplantation, metabolic syndrome, NAFLD, survival, Coronary Artery Disease, CKD, Chronic Kidney Disease, CNI, calcineurin inhibitor, COPD, Chronic Obstructive Pulmonary Disease

الوصف: International audience ; Background and Aims: Liver transplantation (LT) is the treatment of end-stage nonalcoholic liver disease (NAFLD), that is decompensated cirrhosis and/or complicated by hepatocellular carcinoma (HCC). Few data on long-term outcome are available. The aim of this study was to evaluate overall patient and graft survivals and associated predictive factors. Method: This retrospective multicentre study included adult transplant patients for NAFLD cirrhosis between 2000 and 2019 in participating French-speaking centres. Results: A total of 361 patients (69.8% of male) were included in 20 centres. The median age at LT was 62.3 years [57.4-65.9] and the median MELD score was 13.9 [9.1-21.3]; 51.8% of patients had HCC on liver explant. Between 2004 and 2018, the number of LT for NAFLD cirrhosis increased by 720%. A quarter of the patients had cardiovascular history before LT. Median follow-up after LT was 39.1 months [15.8-72.3]. Patient survival at 1, 5 and 10 years after LT was 89.3%, 79.8% and 68.1% respectively. The main causes of death were sepsis (37.5%), malignancies (29.2%) and cardiovascular events (22.2%). In multivariate analysis, three risk factors for overall mortality after LT were recipient pre-LT BMI < 32 kg/m 2 at LT time (OR: 2.272; p = .012), pre-LT angioplasty during CV checkup (OR: 2.916; p = .016), a combined donor and recipient age over 135 years (OR: 2.020; 95%CI: p = .035). Conclusion: Survival after LT for NAFLD cirrhosis is good at 5 years. Donor and recipient age, and cardiovascular history, are major prognostic factors to consider.

العلاقة: hal-04165914; https://hal.science/hal-04165914Test; https://hal.science/hal-04165914/documentTest; https://hal.science/hal-04165914/file/LIV-42-2428.pdfTest

الإتاحة: https://doi.org/10.1111/liv.15385Test
https://hal.science/hal-04165914Test
https://hal.science/hal-04165914/documentTest
https://hal.science/hal-04165914/file/LIV-42-2428.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie‐noëlle, Hiriart, Jean‐baptiste, Houssel‐debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges‐philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Hôpital Claude Huriez Lille, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), CHU Clermont-Ferrand, CHU Trousseau Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg), Les Hôpitaux Universitaires de Strasbourg (HUS), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Hôpital Paul Brousse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département d'Hépato-Gastroentérologie et de Transplantation Hépatique CHU Saint-Eloi, Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Université de Montpellier (UM), Hôpital Beaujon AP-HP, Hôpitaux Universitaires de Genève (HUG), Hôpital Archet 2 Nice (CHU), Hôpital de la Timone CHU - APHM (TIMONE), Centre Hospitalier Universitaire CHU Grenoble (CHUGA), Hôpital Haut-Lévêque CHU Bordeaux, CHU Bordeaux, Service Radiologie et imagerie médicale - Rangueil / Larrey CHU Toulouse, Pôle imagerie médicale CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Ressources Autisme de Bourgogne (CHU de Dijon) (CRAB), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université Paris-Saclay

المصدر: ISSN: 1478-3223.

مصطلحات موضوعية: cardiovascular DRI, donor risk index DSE, dobutamine stress echocardiography GFR, glomerular filtration rate HCC, hepatocellular carcinoma HCV, hepatitis C virus HDL-c, High-Density Lipoproteins Cholesterol ICA, invasive coronary angiography IQR, interquartile range LDL-c, Low-Density Lipoproteins LT, liver transplantation MELD, model for end-stage liver disease MDRD, Modification of Diet in Renal Disease MS, metabolic syndrome mTOR-i, m-TOR inhibitor NAFLD, non-alcoholic fatty Liver disease NASH, nonalcoholic steatohepatitis OSAS, Obstructive Sleep Apnoea syndrome TACE, Trans-Arterial Chemo-Embolization TTE, Transthoracic Echocardiography liver transplantation, metabolic syndrome, NAFLD, survival, Coronary Artery Disease, CKD, Chronic Kidney Disease, CNI, calcineurin inhibitor, COPD, Chronic Obstructive Pulmonary Disease

الوصف: International audience ; Background and Aims: Liver transplantation (LT) is the treatment of end-stage nonalcoholic liver disease (NAFLD), that is decompensated cirrhosis and/or complicated by hepatocellular carcinoma (HCC). Few data on long-term outcome are available. The aim of this study was to evaluate overall patient and graft survivals and associated predictive factors. Method: This retrospective multicentre study included adult transplant patients for NAFLD cirrhosis between 2000 and 2019 in participating French-speaking centres. Results: A total of 361 patients (69.8% of male) were included in 20 centres. The median age at LT was 62.3 years [57.4-65.9] and the median MELD score was 13.9 [9.1-21.3]; 51.8% of patients had HCC on liver explant. Between 2004 and 2018, the number of LT for NAFLD cirrhosis increased by 720%. A quarter of the patients had cardiovascular history before LT. Median follow-up after LT was 39.1 months [15.8-72.3]. Patient survival at 1, 5 and 10 years after LT was 89.3%, 79.8% and 68.1% respectively. The main causes of death were sepsis (37.5%), malignancies (29.2%) and cardiovascular events (22.2%). In multivariate analysis, three risk factors for overall mortality after LT were recipient pre-LT BMI < 32 kg/m 2 at LT time (OR: 2.272; p = .012), pre-LT angioplasty during CV checkup (OR: 2.916; p = .016), a combined donor and recipient age over 135 years (OR: 2.020; 95%CI: p = .035). Conclusion: Survival after LT for NAFLD cirrhosis is good at 5 years. Donor and recipient age, and cardiovascular history, are major prognostic factors to consider.

العلاقة: hal-04165914; https://hal.science/hal-04165914Test; https://hal.science/hal-04165914/documentTest; https://hal.science/hal-04165914/file/LIV-42-2428.pdfTest

الإتاحة: https://doi.org/10.1111/liv.15385Test
https://hal.science/hal-04165914Test
https://hal.science/hal-04165914/documentTest
https://hal.science/hal-04165914/file/LIV-42-2428.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie‐noëlle, Hiriart, Jean‐baptiste, Houssel‐debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges‐philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Hôpital Claude Huriez Lille, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), CHU Clermont-Ferrand, CHU Trousseau Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg), Les Hôpitaux Universitaires de Strasbourg (HUS), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Hôpital Paul Brousse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département d'Hépato-Gastroentérologie et de Transplantation Hépatique CHU Saint-Eloi, Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Université de Montpellier (UM), Hôpital Beaujon AP-HP, Hôpitaux Universitaires de Genève (HUG), Hôpital Archet 2 Nice (CHU), Hôpital de la Timone CHU - APHM (TIMONE), Centre Hospitalier Universitaire CHU Grenoble (CHUGA), Hôpital Haut-Lévêque CHU Bordeaux, CHU Bordeaux, Service Radiologie et imagerie médicale - Rangueil / Larrey CHU Toulouse, Pôle imagerie médicale CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Ressources Autisme de Bourgogne (CHU de Dijon) (CRAB), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université Paris-Saclay

المصدر: ISSN: 1478-3223.

مصطلحات موضوعية: cardiovascular DRI, donor risk index DSE, dobutamine stress echocardiography GFR, glomerular filtration rate HCC, hepatocellular carcinoma HCV, hepatitis C virus HDL-c, High-Density Lipoproteins Cholesterol ICA, invasive coronary angiography IQR, interquartile range LDL-c, Low-Density Lipoproteins LT, liver transplantation MELD, model for end-stage liver disease MDRD, Modification of Diet in Renal Disease MS, metabolic syndrome mTOR-i, m-TOR inhibitor NAFLD, non-alcoholic fatty Liver disease NASH, nonalcoholic steatohepatitis OSAS, Obstructive Sleep Apnoea syndrome TACE, Trans-Arterial Chemo-Embolization TTE, Transthoracic Echocardiography liver transplantation, metabolic syndrome, NAFLD, survival, Coronary Artery Disease, CKD, Chronic Kidney Disease, CNI, calcineurin inhibitor, COPD, Chronic Obstructive Pulmonary Disease

الوصف: International audience ; Background and Aims: Liver transplantation (LT) is the treatment of end-stage nonalcoholic liver disease (NAFLD), that is decompensated cirrhosis and/or complicated by hepatocellular carcinoma (HCC). Few data on long-term outcome are available. The aim of this study was to evaluate overall patient and graft survivals and associated predictive factors. Method: This retrospective multicentre study included adult transplant patients for NAFLD cirrhosis between 2000 and 2019 in participating French-speaking centres. Results: A total of 361 patients (69.8% of male) were included in 20 centres. The median age at LT was 62.3 years [57.4-65.9] and the median MELD score was 13.9 [9.1-21.3]; 51.8% of patients had HCC on liver explant. Between 2004 and 2018, the number of LT for NAFLD cirrhosis increased by 720%. A quarter of the patients had cardiovascular history before LT. Median follow-up after LT was 39.1 months [15.8-72.3]. Patient survival at 1, 5 and 10 years after LT was 89.3%, 79.8% and 68.1% respectively. The main causes of death were sepsis (37.5%), malignancies (29.2%) and cardiovascular events (22.2%). In multivariate analysis, three risk factors for overall mortality after LT were recipient pre-LT BMI < 32 kg/m 2 at LT time (OR: 2.272; p = .012), pre-LT angioplasty during CV checkup (OR: 2.916; p = .016), a combined donor and recipient age over 135 years (OR: 2.020; 95%CI: p = .035). Conclusion: Survival after LT for NAFLD cirrhosis is good at 5 years. Donor and recipient age, and cardiovascular history, are major prognostic factors to consider.

العلاقة: hal-04165914; https://hal.science/hal-04165914Test; https://hal.science/hal-04165914/documentTest; https://hal.science/hal-04165914/file/LIV-42-2428.pdfTest

الإتاحة: https://doi.org/10.1111/liv.15385Test
https://hal.science/hal-04165914Test
https://hal.science/hal-04165914/documentTest
https://hal.science/hal-04165914/file/LIV-42-2428.pdfTest